Cargando…

Intravitreal Bevacizumab in the treatment of neovascular glaucoma secondary to central retinal vein occlusion: a case report

INTRODUCTION: Every eye with central retinal vein occlusion (CRVO) is at risk for developing neovascular glaucoma (NVG). Vascular endothelial growth factor (VEGF) has been shown to play a key role in the development of NVG in CRVO. Bevacizumab (Avastin; Genentech, San Francisco, CA) is a recombinant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alasil, Tarek, Rauser, Michael E
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783132/ https://www.ncbi.nlm.nih.gov/pubmed/19946487 http://dx.doi.org/10.1186/1757-1626-2-176

Ejemplares similares

Intravitreal Bevacizumab for the Treatment of Neovascular Glaucoma Associated With Central Retinal Artery Occlusion
por: Sagong, Min, et al.
Publicado: (2009)

Central retinal thickness changes and risk of neovascular glaucoma after intravitreal bevacizumab injection in patients with central retinal vein occlusion
por: Lee, You Hyun, et al.
Publicado: (2022)

Central retinal vein occlusion: a case report and review of the literature
por: Alasil, Tarek, et al.
Publicado: (2009)

Prospective evaluation of intravitreal bevacizumab for ischemic central retinal vein occlusion
por: Hall, Leangelo, et al.
Publicado: (2019)

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
por: Gutiérrez, Juan Carlos Mesa, et al.
Publicado: (2008)

Neovascular glaucoma after central retinal vein occlusion in pre-existing glaucoma
por: Chen, Hsi-Fu, et al.
Publicado: (2014)

Comparison of the effects of intravitreal bevacizumab and triamcinolone acetonide in the treatment of macular edema secondary to central retinal vein occlusion
por: Demir, Mehmet, et al.
Publicado: (2014)

Neovascular Events in Eyes with Central Retinal Vein Occlusion Undergoing Serial Bevacizumab or Ranibizumab Intravitreal Injections: A Retrospective Review
por: DeCroos, Francis Char, et al.
Publicado: (2014)

Efficacy and visual prognostic factors of intravitreal bevacizumab as needed for macular edema secondary to central retinal vein occlusion
por: Hirose, Miki, et al.
Publicado: (2014)

Progression of Impending Central Retinal Vein Occlusion to the Ischemic Variant Following Intravitreal Bevacizumab
por: Kim, Na Rae, et al.
Publicado: (2010)

Rapid regression of retinal neovascularization following intravitreal bevacizumab in branch retinal vein occlusion imaged by optical coherence tomography angiography
por: Brar, Manpreet, et al.
Publicado: (2018)

Real-world outcomes of intravitreal bevacizumab treat-and-extend for cystoid macular oedema secondary to central retinal vein occlusion
por: Gildea, David, et al.
Publicado: (2023)

Comparison Between Intravitreal Bevacizumab and Triamcinolone for Macular Edema Secondary to Branch Retinal Vein Occlusion
por: Kim, Jin Young, et al.
Publicado: (2009)

Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results
por: Thapa, Raba, et al.
Publicado: (2012)

The comparison of intravitreal triamcinolone and bevacizumab in patients with macular edema secondary to branch retinal vein occlusion
por: Gokce, Gokcen, et al.
Publicado: (2014)

Comparison of the Efficacy of Intravitreal Aflibercept and Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
por: Wang, Jia-Kang, et al.
Publicado: (2016)

Short-term efficacy of intravitreal triamcinolone acetonide for macular edema secondary to retinal vein occlusion that is refractory to intravitreal bevacizumab
por: Yoo, Seul Gi, et al.
Publicado: (2015)

Rebound effect following intravitreal bevacizumab in branch retinal vein occlusion
por: Deka, Satyen, et al.
Publicado: (2009)

Intravitreal Bevacizumab (Avastin) as an Adjuvant Treatment in Cases of Neovascular Glaucoma
por: Ghanem, Asaad A., et al.
Publicado: (2009)

Efficacy of combined intravitreal bevacizumab and triamcinolone for branch retinal vein occlusion
por: Ali, Rasha I, et al.
Publicado: (2014)

Intravitreal bevacizumab upregulates transthyretin in experimental branch retinal vein occlusion
por: Cehofski, Lasse Jørgensen, et al.
Publicado: (2018)

Intravitreal bevacizumab as therapy for refractory neovascular glaucoma secondary to iris metastasis of breast carcinoma
por: Vale, Stephanie, et al.
Publicado: (2018)

Effects of intravitreal bevacizumab on reduced visual acuity and macular thickness secondary to branch retinal vein occlusion
por: Eltutar, Kadir, et al.
Publicado: (2013)

Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion
por: Hikichi, Taiichi, et al.
Publicado: (2014)

Dexamethasone Intravitreal Implant Rescue Treatment for Bevacizumab Refractory Macular Edema Secondary to Branch Retinal Vein Occlusion
por: Lee, Kyou Ho, et al.
Publicado: (2017)

Macular Hole Progression after Intravitreal Bevacizumab for Hemicentral Retinal Vein Occlusion
por: Nagpal, Manish, et al.
Publicado: (2011)

Intravitreal bevacizumab injection and carotid artery stent replacement for neovascular glaucoma in internal carotid artery occlusion
por: Kodama, Aya, et al.
Publicado: (2010)

Intravitreal Bevacizumab (Avastin) Treatment of Neovascular Glaucoma in Ocular Ischemic Syndrome
por: Lee, Sang Joon, et al.
Publicado: (2009)

Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma
por: Marey, Hatem M, et al.
Publicado: (2011)

Neovascular Glaucoma Due to Branch Retinal Vein Occlusion Combined with Branch Retinal Artery Occlusion
por: An, Tae-Su, et al.
Publicado: (2013)

Accelerated ischemic vascular retinopathy after intravitreally injected bevacizumab for central retinal vein occlusion in elderly patients
por: Isola, Vincenzo, et al.
Publicado: (2013)

Treatment of total exudative retinal detachment due to central retinal vein occlusion by intravitreal bevacizumab in a patient with p-ANCA vasculitis
por: Ferencz, Joseph R, et al.
Publicado: (2007)

The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
por: Ivanovska Adjievska, Biljana, et al.
Publicado: (2017)

Anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma
por: Canut, MI, et al.
Publicado: (2011)

Initial Dose of Three Monthly Intravitreal Injections versus PRN Intravitreal Injections of Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
por: Ahn, Seong Joon, et al.
Publicado: (2013)

Oral Vitamin D Supplementation and Clinical Outcomes of Intravitreal Bevacizumab Injection for Macular Edema Secondary to Retinal Vein Occlusions
por: Karimi, Saeed, et al.
Publicado: (2022)

RETINAL BLOOD FLOW AFTER INTRAVITREAL BEVACIZUMAB IS A PREDICTIVE FACTOR FOR OUTCOMES OF MACULAR EDEMA ASSOCIATED WITH CENTRAL RETINAL VEIN OCCLUSION
por: Matsumoto, Makiko, et al.
Publicado: (2018)

Glaucoma drainage device implantation with adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience
por: Noor, Nina Asrini, et al.
Publicado: (2017)

Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results
por: Demir, Mehmet, et al.
Publicado: (2011)

Grid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion
por: Ogino, Ken, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_44br75pbji723lpat2fndeglt0